UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications

Int J Tuberc Lung Dis. 2012;16(3):376-8. doi: 10.5588/ijtld.11.0404. Epub 2012 Jan 5.

Abstract

First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl-transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antitubercular Agents / adverse effects*
  • Antitubercular Agents / therapeutic use
  • Chemical and Drug Induced Liver Injury / etiology*
  • Chemical and Drug Induced Liver Injury / genetics
  • Female
  • Genetic Predisposition to Disease
  • Glucuronosyltransferase / genetics*
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Retrospective Studies
  • Risk Factors
  • Tuberculosis / drug therapy*

Substances

  • Antitubercular Agents
  • UGT1A1 enzyme
  • Glucuronosyltransferase